Tirzepatide Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Tirzepatide comprises 239 peer-reviewed publications across 15 journals, 27 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Obesity, Diabetes Mellitus, Type 2, Overweight, and Headache. Most recent publication: Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism., Cell Metab, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping.
    Zwanenburg A, Vallières M, Abdalah MA, et al. · Radiology · 2020
    PubMed: PMID 32154773 · NCT07567378 (CARTIZ) · Obesity
  2. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.
    Regmi A, Aihara E, Christe ME, et al. · Cell Metab · 2024
    PubMed: PMID 38878772 · NCT07567378 (CARTIZ) · Obesity
  3. Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism.
    Qin H, Yu J, Yu H, et al. · Cell Metab · 2026
    PubMed: PMID 41666927 · NCT07567378 (CARTIZ) · Obesity
  4. Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.
    Packer M, Zile MR, Kramer CM, et al. · J Am Coll Cardiol · 2025
    PubMed: PMID 40903131 · NCT07567378 (CARTIZ) · Obesity
  5. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.
    Merola JF, Mease P, Kivitz A, et al. · Arthritis Rheumatol · 2026
    PubMed: PMID 41903163 · NCT07567378 (CARTIZ) · Obesity
  6. Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.
    Kramer CM, Borlaug BA, Zile MR, et al. · J Am Coll Cardiol · 2025
    PubMed: PMID 39566869 · NCT07567378 (CARTIZ) · Obesity
  7. Detecting human coronary inflammation by imaging perivascular fat.
    Antonopoulos AS, Sanna F, Sabharwal N, et al. · Sci Transl Med · 2018
    PubMed: PMID 28701474 · NCT07567378 (CARTIZ) · Obesity
  8. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.
    Nissen SE, Wolski K, D'Alessio D, et al. · JAMA Cardiol · 2026
    PubMed: PMID 41903177 · NCT04255433 (SURPASS-CVOT) · Diabetes Mellitus, Type 2

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT03730662
SURPASS-4
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
Baseline, Week 52
10 mg Tirzepatide-2.43 Percentage of HbA1c (±0.053 Standard Error)
15 mg Tirzepatide-2.58 Percentage of HbA1c (±0.053 Standard Error)
Insulin Glargine-1.44 Percentage of HbA1c (±0.030 Standard Error)
NCT03861039Diabetes Mellitus, Type 2Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline through Week 52
10 mg Tirzepatide1 Participants
15 mg Tirzepatide1 Participants
5 mg Tirzepatide0 Participants
NCT03861052
SURPASS J-mono
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c)
Baseline, Week 52
0.75 mg Dulaglutide-1.29 percentage of HbA1c (±0.065 Standard Error)
10 mg Tirzepatide-2.55 percentage of HbA1c (±0.067 Standard Error)
15 mg Tirzepatide-2.82 percentage of HbA1c (±0.066 Standard Error)
5 mg Tirzepatide-2.37 percentage of HbA1c (±0.066 Standard Error)
NCT03882970
SURPASS-3
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
Baseline, Week 52
10 mg Tirzepatide-2.20 Percentage of HbA1c (±0.051 Standard Error)
15 mg Tirzepatide-2.37 Percentage of HbA1c (±0.050 Standard Error)
Insulin Degludec-1.34 Percentage of HbA1c (±0.049 Standard Error)
NCT03954834
SURPASS-1
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c)
Baseline, Week 40
10 mg Tirzepatide-1.89 Percentage of HbA1c (±0.096 Standard Error)
15 mg Tirzepatide-2.07 Percentage of HbA1c (±0.098 Standard Error)
5 mg Tirzepatide-1.87 Percentage of HbA1c (±0.094 Standard Error)
Placebo0.04 Percentage of HbA1c (±0.105 Standard Error)
NCT03987919
SURPASS-2
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
Baseline, Week 40
1 mg Semaglutide-1.86 Percentage of HbA1c (±0.048 Standard Error)
10 mg Tirzepatide-2.37 Percentage of HbA1c (±0.048 Standard Error)
15 mg Tirzepatide-2.46 Percentage of HbA1c (±0.048 Standard Error)
NCT04039503
SURPASS-5
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
Baseline, Week 40
10 mg Tirzepatide-2.59 Percentage of HbA1c (±0.081 Standard Error)
15 mg Tirzepatide-2.59 Percentage of HbA1c (±0.083 Standard Error)
Placebo-0.93 Percentage of HbA1c (±0.079 Standard Error)
NCT04093752Diabetes Mellitus, Type 2Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
Baseline, Week 40
10 mg Tirzepatide-2.44 Percentage of HbA1c (±0.073 Standard Error)
15 mg Tirzepatide-2.49 Percentage of HbA1c (±0.072 Standard Error)
Insulin Glargine-0.95 Percentage of HbA1c (±0.073 Standard Error)
NCT04184622
SURMOUNT-1
ObesityPercent Change From Baseline in Body Weight (Primary Treatment Period)
Baseline, Week 72
10 mg Tirzepatide-21.4 percent change (±0.39 Standard Error)
15 mg Tirzepatide-22.5 percent change (±0.39 Standard Error)
5 mg Tirzepatide-16.0 percent change (±0.39 Standard Error)
Placebo-2.4 percent change (±0.40 Standard Error)
NCT04184622
SURMOUNT-1
ObesityPercentage of Participants Who Achieve ≥5% Body Weight Reduction (Primary Treatment Period)
Week 72
10 mg Tirzepatide96.18 Percentage of Participants
15 mg Tirzepatide96.32 Percentage of Participants
5 mg Tirzepatide89.41 Percentage of Participants
Placebo27.87 Percentage of Participants
NCT04537923
SURPASS-6
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg)
Baseline, Week 52
Insulin Lispro-1.16 Percentage of HbA1c (±0.049 Standard Error)
Pooled 5 mg/10 mg/15 mg Tirzepatide-2.26 Percentage of HbA1c (±0.048 Standard Error)
NCT04657003
SURMOUNT-2
ObesityPercent Change From Baseline in Body Weight
Baseline, Week 72
10 mg Tirzepatide-13.4 percent change (±0.48 Standard Error)
15 mg Tirzepatide-15.7 percent change (±0.49 Standard Error)
Placebo-3.3 percent change (±0.49 Standard Error)
NCT04657003
SURMOUNT-2
ObesityPercentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline
Week 72
10 mg Tirzepatide81.55 percentage of participants
15 mg Tirzepatide86.41 percentage of participants
Placebo30.55 percentage of participants
NCT04657016
SURMOUNT-3
ObesityPercent Change From Baseline in Body Weight
Baseline, 72 Weeks
Placebo3.3 Percent change (±0.60 Standard Error)
Tirzepatide-21.1 Percent change (±0.59 Standard Error)
NCT04657016
SURMOUNT-3
ObesityPercentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction
Week 72
Placebo10.65 percentage of participants
Tirzepatide94.37 percentage of participants
NCT04660643
SURMOUNT-4
ObesityPercent Change From Randomization in Body Weight at Week 88
Randomization (Week 36), Week 88
Placebo14.8 percent change (±0.53 Standard Error)
Tirzepatide MTD-6.7 percent change (±0.52 Standard Error)
NCT04844918
SURMOUNT-J
ObesityMean Percent Change in Body Weight
Baseline, 72 Weeks
10 mg Tirzepatide-17.8 Percent change (±0.94 Standard Error)
15 mg Tirzepatide-22.7 Percent change (±0.90 Standard Error)
Placebo-1.7 Percent change (±0.90 Standard Error)
NCT04844918
SURMOUNT-J
ObesityPercentage of Participants Who Achieve ≥5% Body Weight Reduction
Week 72
10 mg Tirzepatide94.37 Percentage of participants
15 mg Tirzepatide96.05 Percentage of participants
Placebo20 Percentage of participants
NCT04847557ObesityChange From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)
Baseline, Week 52
Placebo12.68 Score on a scale (±1.25 Standard Error)
Tirzepatide - MTD19.51 Score on a scale (±1.24 Standard Error)
NCT04847557ObesityFirst Occurrence of the Composite Endpoint of Heart Failure (HF) Outcomes
Baseline Up To 160 weeks
Placebo56 Number of events
Tirzepatide - MTD36 Number of events
NCT05024032
SURMOUNT-CN
ObesityMean Percent Change From Baseline in Body Weight
Baseline, Week 52
10 mg Tirzepatide-14.4 Percent change (±0.98 Standard Error)
15 mg Tirzepatide-19.9 Percent change (±1.01 Standard Error)
Placebo-2.4 Percent change (±1.00 Standard Error)
NCT05024032
SURMOUNT-CN
ObesityPercentage of Participants Who Achieve ≥5% Body Weight Reduction
Week 52
10 mg Tirzepatide91.43 Percentage of participants
15 mg Tirzepatide92.65 Percentage of participants
Placebo29.41 Percentage of participants
NCT05260021
SURPASS-PEDS
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg)
Baseline, Week 30
Placebo-0.23 percentage of HbA1c (±0.229 Standard Error)
Pooled Doses of Tirzepatide (5 mg, 10 mg)-2.03 percentage of HbA1c (±0.165 Standard Error)
NCT05412004
SURMOUNT-OSA
ObesityChange From Baseline in Apnea-Hypopnea Index (AHI)
Baseline, Week 52
Placebo_GPI1-5.25 events per hour (±2.11 Standard Error)
Placebo_GPI2-5.51 events per hour (±2.21 Standard Error)
Tirzepatide MTD_GPI1-25.25 events per hour (±2.06 Standard Error)
Tirzepatide MTD_GPI2-29.27 events per hour (±1.99 Standard Error)
NCT05691712
SURPASS-CN-INS
Diabetes Mellitus, Type 2Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg])
Baseline, Week 40
10 mg Tirzepatide-26.1 millimoles per mole (mmol/mol) (±1.367 Standard Error)
15 mg Tirzepatide-25.9 millimoles per mole (mmol/mol) (±1.386 Standard Error)
Placebo-9.96 millimoles per mole (mmol/mol) (±1.340 Standard Error)
NCT05822830
SURMOUNT-5
ObesityPercent Change From Baseline in Body Weight
Baseline, Week 72
15 mg or MTD - Tirzepatide-20.2 Percent change (±0.59 Standard Error)
2.4 mg or MTD - Semaglutide-13.7 Percent change (±0.59 Standard Error)
NCT05963022Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c)
Baseline, Week 40
10 mg Tirzepatide-1.75 percentage of HbA1c (±0.131 Standard Error)
15 mg Tirzepatide-2.03 percentage of HbA1c (±0.124 Standard Error)
5 mg Tirzepatide-2.19 percentage of HbA1c (±0.121 Standard Error)
Placebo-0.77 percentage of HbA1c (±0.126 Standard Error)

Publications by year

1988–2026: 239 publications.

1988
1
1998
1
2000
2
2001
1
2004
1
2005
1
2007
2
2008
3
2009
3
2010
3
2011
2
2012
2
2013
3
2014
2
2015
5
2016
7
2017
3
2018
8
2019
11
2020
10
2021
28
2022
26
2023
21
2024
28
2025
45
2026
20

Publications by indication

Obesity (149)

  • Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism.
    Cell Metab · 2026 · PMID 41666927 · NCT07567378
  • Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.
    Arthritis Rheumatol · 2026 · PMID 41903163 · NCT07567378
  • Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.
    Diabetes Obes Metab · 2026 · PMID 41290555 · NCT04844918
  • Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.
    Obesity (Silver Spring) · 2026 · PMID 41537305 · NCT04657016
  • Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.
    Nat Med · 2026 · PMID 41540105 · NCT05412004

Diabetes Mellitus, Type 2 (45)

  • Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.
    BMJ Open Diabetes Res Care · 2026 · PMID 41912265 · NCT05564039
  • Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.
    JAMA Cardiol · 2026 · PMID 41903177 · NCT04255433
  • Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
    Diabetes Ther · 2026 · PMID 37526908 · NCT03730662
  • Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
    Diabetes Ther · 2026 · PMID 37668888 · NCT03882970
  • Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin: Pooled Subgroup Analysis of SURPASS-5 and -6.
    Diabetes Ther · 2026 · PMID 41961454 · NCT04537923

Overweight (20)

  • Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.
    Nat Med · 2026 · PMID 41207920 · NCT07096063
  • Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes.
    Diabetes Technol Ther · 2025 · PMID 39745353 · NCT07284511
  • Effect of Tirzepatide on Body Weight and Diabetes Control in Adults With Type 1 Diabetes and Overweight or Obesity.
    Mayo Clin Proc · 2025 · PMID 39601745 · NCT07284511
  • Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.
    Nat Med · 2025 · PMID 39794615 · NCT07284511
  • Changes in Basal and Bolus Insulin Requirements with Tirzepatide as an Adjunctive Therapy in Adults with Type 1 Diabetes Using Tandem Control-IQ.
    Diabetes Ther · 2024 · PMID 38743306 · NCT07284511

Headache (5)

  • Incidence, Prevalence, and Health Care Outcomes in Idiopathic Intracranial Hypertension: A Population Study.
    Neurology · 2025 · PMID 33472926 · NCT07191873
  • The expanding burden of idiopathic intracranial hypertension.
    Eye (Lond) · 2019 · PMID 30356129 · NCT07191873
  • Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management.
    J Neurol Neurosurg Psychiatry · 2017 · PMID 26888960 · NCT07191873
  • Controversies: Optic nerve sheath fenestration versus shunt placement for the treatment of idiopathic intracranial hypertension.
    Indian J Ophthalmol · 2016 · PMID 25449938 · NCT07191873
  • Epidemiology and risk factors for idiopathic intracranial hypertension.
    Int Ophthalmol Clin · 2014 · PMID 24296367 · NCT07191873

Diabetes Mellitus (1)

  • Effect of Ebenatide on glycemic metabolism and body fat in patients with type 2 diabetes mellitus.
    Front Endocrinol (Lausanne) · 2025 · PMID 40607222 · NCT05990374

Kidney Failure, Chronic (1)

  • Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
    Clin Pharmacokinet · 2021 · PMID 33778934 · NCT03482024

Publications by journal

Trial-results highlights

For patients with Type 2 Diabetes Mellitus, studies investigated the effect of Tirzepatide on Hemoglobin A1c (HbA1c) levels. In the SURPASS-4 trial (NCT03730662), at Week 52, 10 mg Tirzepatide led to a -2.43% change from baseline in HbA1c, and 15 mg Tirzepatide led to a -2.58% change, compared to -1.44% with Insulin Glargine. Another study, NCT04093752, reported at Week 40 a -2.44% change for 10 mg Tirzepatide and a -2.49% change for 15 mg Tirzepatide, versus -0.95% with Insulin Glargine. In the SURPASS-3 trial (NCT03882970), at Week 52, 10 mg Tirzepatide showed a -2.20% change and 15 mg Tirzepatide showed a -2.37% change in HbA1c, while Insulin Degludec showed a -1.34% change. The SURPASS J-mono trial (NCT03861052) reported at Week 52 a -2.37% change for 5 mg Tirzepatide, a -2.55% change for 10 mg Tirzepatide, and a -2.82% change for 15 mg Tirzepatide, compared to -1.29% with 0.75 mg Dulaglutide.

Further studies examined HbA1c changes. In the SURPASS-2 trial (NCT03987919), at Week 40, 10 mg Tirzepatide resulted in a -2.37% change from baseline in HbA1c, and 15 mg Tirzepatide resulted in a -2.46% change, while 1 mg Semaglutide showed a -1.86% change. The SURPASS-1 trial (NCT03954834) reported at Week 40 a -1.87% change for 5 mg Tirzepatide, a -1.89% change for 10 mg Tirzepatide, and a -2.07% change for 15 mg Tirzepatide, compared to 0.04% with placebo. In the SURPASS-5 trial (NCT04039503), at Week 40, 10 mg Tirzepatide and 15 mg Tirzepatide both showed a -2.59% change in HbA1c, versus -0.93% with placebo.

Regarding safety, in a study (NCT03861039) evaluating serious adverse events (SAEs) considered related to study drug administration, 1 participant in the 10 mg Tirzepatide arm and 1 participant in the 15 mg Tirzepatide arm experienced one or more SAEs from baseline through Week 52. No participants in the 5 mg Tirzepatide arm experienced such SAEs. All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Tirzepatide publications (239)

2026 (20 papers)

  1. Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism.
    Qin H, Yu J, Yu H, et al. · Cell Metab · 2026 · Trial result
    PubMed: PMID 41666927 · NCT07567378 (CARTIZ) · Obesity
  2. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.
    Merola JF, Mease P, Kivitz A, et al. · Arthritis Rheumatol · 2026 · Trial result
    PubMed: PMID 41903163 · NCT07567378 (CARTIZ) · Obesity
  3. Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.
    Yokote K, Fukushima Y, Shingaki T, et al. · Diabetes Obes Metab · 2026 · Derived
    PubMed: PMID 41290555 · NCT04844918 (SURMOUNT-J) · Obesity
  4. Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.
    Wadden TA, Oquendo MA, Kushner RF, et al. · Obesity (Silver Spring) · 2026 · Derived
    PubMed: PMID 41537305 · NCT04657016 (SURMOUNT-3) · Obesity
  5. Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.
    Violante-Ortiz R, Rose L, Sharma P, et al. · BMJ Open Diabetes Res Care · 2026 · Derived
    PubMed: PMID 41912265 · NCT05564039 (SURPASS-SWITCH) · Diabetes Mellitus, Type 2
  6. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.
    Nissen SE, Wolski K, D'Alessio D, et al. · JAMA Cardiol · 2026 · Derived
    PubMed: PMID 41903177 · NCT04255433 (SURPASS-CVOT) · Diabetes Mellitus, Type 2
  7. Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.
    Malhotra A, Grunstein R, Azarbarzin A, et al. · Nat Med · 2026 · Derived
    PubMed: PMID 41540105 · NCT05412004 (SURMOUNT-OSA) · Obesity
  8. Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.
    Krüger N, Schneeweiss S, Desai RJ, et al. · Nat Med · 2026 · Derived
    PubMed: PMID 41207920 · NCT07096063 (TIRZSEMA-CVOT) · Overweight
  9. Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients With Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial.
    Jain V, McMullen CA, Kimbrough JI, et al. · J Surg Res · 2026 · Derived
    PubMed: PMID 41643256 · NCT06721507 · Obesity
  10. Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.
    Ishigaki Y, Yamada M, Shingaki T, et al. · Obesity (Silver Spring) · 2026 · Derived
    PubMed: PMID 41612966 · NCT04184622 (SURMOUNT-1) · Obesity
  11. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.
    Horn DB, Linetzky B, Davies MJ, et al. · JAMA Intern Med · 2026 · Derived
    PubMed: PMID 41284285 · NCT04660643 (SURMOUNT-4) · Obesity
  12. Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes.
    Heerspink HJL, Friedman AN, Bjornstad P, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 40512543 · NCT04657003 (SURMOUNT-2) · Obesity
  13. Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.
    Galindo RJ, Gudzune KA, Look M, et al. · JAMA Netw Open · 2026 · Derived
    PubMed: PMID 41885866 · NCT04657016 (SURMOUNT-3) · Obesity
  14. The Need for Novel Therapeutic Directions in Autosomal Dominant Polycystic Kidney Disease Patient Care.
    Cortinovis M, Perico N, Remuzzi G, et al. · Clin J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41348481 · NCT06582875 · Obesity
  15. Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
    Boye KS, Thieu VT, Sapin H, et al. · Diabetes Ther · 2026 · Derived
    PubMed: PMID 37526908 · NCT03730662 (SURPASS-4) · Diabetes Mellitus, Type 2
  16. Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
    Boye KS, Sapin H, Dong W, et al. · Diabetes Ther · 2026 · Derived
    PubMed: PMID 37668888 · NCT03882970 (SURPASS-3) · Diabetes Mellitus, Type 2
  17. Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin: Pooled Subgroup Analysis of SURPASS-5 and -6.
    Bajaj HS, Billings LK, Sharma P, et al. · Diabetes Ther · 2026 · Derived
    PubMed: PMID 41961454 · NCT04537923 (SURPASS-6) · Diabetes Mellitus, Type 2
  18. Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.
    Aronne LJ, Horn DB, Kokkinos AD, et al. · Am J Med · 2026 · Derived
    PubMed: PMID 41865857 · NCT05822830 (SURMOUNT-5) · Obesity
  19. Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials.
    Almandoz JP, Pickett-Blakely O, Tewksbury C, et al. · Obes Pillars · 2026 · Derived
    PubMed: PMID 41640675 · NCT04657016 (SURMOUNT-3) · Obesity
  20. GLP-1R agonist medications for addiction treatment.
    Volkow ND, Xu R · Addiction · 2026 · Background
    PubMed: PMID 39049203 · NCT06745128 · Obesity

2025 (45 papers)

  1. Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.
    Packer M, Zile MR, Kramer CM, et al. · J Am Coll Cardiol · 2025 · Trial result
    PubMed: PMID 40903131 · NCT07567378 (CARTIZ) · Obesity
  2. Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.
    Kramer CM, Borlaug BA, Zile MR, et al. · J Am Coll Cardiol · 2025 · Trial result
    PubMed: PMID 39566869 · NCT07567378 (CARTIZ) · Obesity
  3. Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.
    Zile MR, Borlaug BA, Kramer CM, et al. · Circulation · 2025 · Derived
    PubMed: PMID 39556714 · NCT04847557 · Obesity
  4. Effect of Ebenatide on glycemic metabolism and body fat in patients with type 2 diabetes mellitus.
    Xu CL, Kong XC, Liu XM, et al. · Front Endocrinol (Lausanne) · 2025 · Derived
    PubMed: PMID 40607222 · NCT05990374 · Diabetes Mellitus
  5. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial.
    Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. · Lancet Diabetes Endocrinol · 2025 · Derived
    PubMed: PMID 40318682 · NCT03882970 (SURPASS-3) · Diabetes Mellitus, Type 2
  6. Tirzepatide for the treatment of adults living with concurrent type 1 diabetes and overweight or obesity (TZP-T1D): a double-blind, placebo-matched randomised controlled trial protocol.
    Purcell AR, Rodrigo N, Longfield MSG, et al. · BMJ Open · 2025 · Derived
    PubMed: PMID 40962353 · NCT06180616 (TZP-T1D) · Obesity
  7. Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide.
    Pieber TR, Svehlikova E, Urva S, et al. · Front Endocrinol (Lausanne) · 2025 · Derived
    PubMed: PMID 40964167 · NCT04050553 · Diabetes Mellitus, Type 2
  8. Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.
    Packer M, Zile MR, Kramer CM, et al. · J Am Coll Cardiol · 2025 · Derived
    PubMed: PMID 40162940 · NCT04847557 · Obesity
  9. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
    Packer M, Zile MR, Kramer CM, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 39555826 · NCT04847557 · Obesity
  10. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
    Nicholls SJ, Pavo I, Bhatt DL, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 41406444 · NCT04255433 (SURPASS-CVOT) · Diabetes Mellitus, Type 2
  11. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
    Natale P, Green SC, Tunnicliffe DJ, et al. · Cochrane Database Syst Rev · 2025 · Derived
    PubMed: PMID 39963952 · NCT05536804 (TREASURE-CKD) · Obesity
  12. Association Between Early Weight Loss and Metabolic Outcomes with Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J Post Hoc Analysis.
    Mimura H, Oura T, Chin R, et al. · Diabetes Ther · 2025 · Derived
    PubMed: PMID 40711720 · NCT03861052 (SURPASS J-mono) · Diabetes Mellitus, Type 2
  13. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.
    Martin CK, Carmichael OT, Carnell S, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 40555748 · NCT04311411 · Obesity
  14. Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial.
    Mamas MA, Bays H, Li R, et al. · Eur Heart J Open · 2025 · Derived
    PubMed: PMID 40980721 · NCT05822830 (SURMOUNT-5) · Obesity
  15. Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight.
    Malhotra A, Grunstein RR, Azarbarzin A, et al. · Sleep Med · 2025 · Derived
    PubMed: PMID 41135142 · NCT05412004 (SURMOUNT-OSA) · Obesity
  16. Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide.
    Linetzky B, Sattar N, Verma S, et al. · Ann Intern Med · 2025 · Derived
    PubMed: PMID 40550133 · NCT04184622 (SURMOUNT-1) · Obesity
  17. People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment.
    Li X, Cao D, Sapin H, et al. · Obesity (Silver Spring) · 2025 · Derived
    PubMed: PMID 41187013 · NCT04657016 (SURMOUNT-3) · Obesity
  18. Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.
    Krüger N, Schneeweiss S, Fuse K, et al. · JAMA · 2025 · Derived
    PubMed: PMID 40886075 · NCT06914141 (DUP-TIRZSEMA) · Diabetes Mellitus, Type 2
  19. Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration.
    Khawaji A, A Jaly A, A Bakri H, et al. · J Obes · 2025 · Derived
    PubMed: PMID 40746703 · NCT04255433 (SURPASS-CVOT) · Diabetes Mellitus, Type 2
  20. Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.
    Kanu C, Shinde S, Chakladar S, et al. · Sleep Med · 2025 · Derived
    PubMed: PMID 40774158 · NCT05412004 (SURMOUNT-OSA) · Obesity
  21. Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
    Kadowaki T, Kiyosue A, Shingaki T, et al. · Lancet Diabetes Endocrinol · 2025 · Derived
    PubMed: PMID 40031941 · NCT04844918 (SURMOUNT-J) · Obesity
  22. Tirzepatide for Obesity Treatment and Diabetes Prevention.
    Jastreboff AM, le Roux CW, Stefanski A, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 39536238 · NCT04184622 (SURMOUNT-1) · Obesity
  23. Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial.
    Hunter Gibble T, Cao D, Zhang XM, et al. · Diabetes Ther · 2025 · Derived
    PubMed: PMID 40120035 · NCT04657003 (SURMOUNT-2) · Obesity
  24. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.
    Horn DB, Kahan S, Batterham RL, et al. · Clin Obes · 2025 · Derived
    PubMed: PMID 39800653 · NCT04184622 (SURMOUNT-1) · Obesity
  25. Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAIN.
    Horn DB, Aronne LJ, Wharton S, et al. · Obesity (Silver Spring) · 2025 · Derived
    PubMed: PMID 40916045 · NCT06047548 · Obesity
  26. Effect of tirzepatide-induced weight loss on adipose tissue in obesity: rationale and design of the randomized placebo-controlled Tirzepatide Brown and Beige Adipose Tissue Activation (TABFAT) trial.
    Herman R, Jensterle M, Horvat S, et al. · Trials · 2025 · Derived
    PubMed: PMID 40847412 · NCT06893211 (TABFAT) · Obesity
  27. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Hannon TS, Chao LC, Barrientos-Pérez M, et al. · Lancet · 2025 · Derived
    PubMed: PMID 40975112 · NCT05260021 (SURPASS-PEDS) · Diabetes Mellitus, Type 2
  28. Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis.
    Hamamoto Y, Oura T, Hirase T, et al. · Diabetes Ther · 2025 · Derived
    PubMed: PMID 39951042 · NCT03861052 (SURPASS J-mono) · Diabetes Mellitus, Type 2
  29. Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.
    Guo L, Dong X, Ma J, et al. · Lancet Diabetes Endocrinol · 2025 · Derived
    PubMed: PMID 41167231 · NCT05691712 (SURPASS-CN-INS) · Diabetes Mellitus, Type 2
  30. Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study.
    Gudzune KA, Stefanski A, Cao D, et al. · Diabetes Obes Metab · 2025 · Derived
    PubMed: PMID 39497468 · NCT04184622 (SURMOUNT-1) · Obesity
  31. Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials.
    Gourgari E, Srivastava G, Kelly AS, et al. · Obesity (Silver Spring) · 2025 · Derived
    PubMed: PMID 40717199 · NCT04184622 (SURMOUNT-1) · Obesity
  32. Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4.
    Gibble TH, Cao D, Murphy M, et al. · Obesity (Silver Spring) · 2025 · Derived
    PubMed: PMID 40903801 · NCT04660643 (SURMOUNT-4) · Obesity
  33. Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics.
    De Block C, Peleshok J, Wilding JPH, et al. · Diabetes Ther · 2025 · Derived
    PubMed: PMID 39531161 · NCT03882970 (SURPASS-3) · Diabetes Mellitus, Type 2
  34. Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial.
    Borlaug BA, Zile MR, Kramer CM, et al. · J Am Coll Cardiol · 2025 · Derived
    PubMed: PMID 40701669 · NCT04847557 · Obesity
  35. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.
    Borlaug BA, Zile MR, Kramer CM, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 39551891 · NCT04847557 · Obesity
  36. Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial.
    Billings LK, Winne L, Sharma P, et al. · Ann Intern Med · 2025 · Derived
    PubMed: PMID 40183678 · NCT05564039 (SURPASS-SWITCH) · Diabetes Mellitus, Type 2
  37. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
    Aronne LJ, Horn DB, le Roux CW, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 40353578 · NCT05822830 (SURMOUNT-5) · Obesity
  38. Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.
    Ard J, Lee CJ, Gudzune K, et al. · Diabetes Obes Metab · 2025 · Derived
    PubMed: PMID 40677091 · NCT04184622 (SURMOUNT-1) · Obesity
  39. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes.
    Snell-Bergeon JK, Kaur G, Renner D, et al. · Diabetes Technol Ther · 2025 · Background
    PubMed: PMID 39745353 · NCT07284511 (TZP) · Overweight
  40. Obesity substantially impacts rheumatic and musculoskeletal diseases: time to act.
    Sattar N, Sattar LJ, McInnes IB, et al. · Ann Rheum Dis · 2025 · Background
    PubMed: PMID 40090785 · NCT07443956 (COMBAT-PsA) · Obesity
  41. Effect of Tirzepatide on Body Weight and Diabetes Control in Adults With Type 1 Diabetes and Overweight or Obesity.
    Rivera Gutierrez R, Tama E, Bechenati D, et al. · Mayo Clin Proc · 2025 · Background
    PubMed: PMID 39601745 · NCT07284511 (TZP) · Overweight
  42. Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.
    Pasqua MR, Tsoukas MA, Kobayati A, et al. · Nat Med · 2025 · Background
    PubMed: PMID 39794615 · NCT07284511 (TZP) · Overweight
  43. Incidence, Prevalence, and Health Care Outcomes in Idiopathic Intracranial Hypertension: A Population Study.
    Miah L, Strafford H, Fonferko-Shadrach B, et al. · Neurology · 2025 · Background
    PubMed: PMID 33472926 · NCT07191873 (TIIHT) · Headache
  44. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.
    McGowan B, Ciudin A, Baker JL, et al. · Nat Med · 2025 · Background
    PubMed: PMID 41039116 · NCT07504172 (TIRZ-DOSE-NL) · Obesity
  45. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder.
    Lähteenvuo M, Tiihonen J, Solismaa A, et al. · JAMA Psychiatry · 2025 · Background
    PubMed: PMID 39535805 · NCT06745128 · Obesity

2024 (28 papers)

  1. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.
    Regmi A, Aihara E, Christe ME, et al. · Cell Metab · 2024 · Trial result
    PubMed: PMID 38878772 · NCT07567378 (CARTIZ) · Obesity
  2. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.
    Zhao L, Cheng Z, Lu Y, et al. · JAMA · 2024 · Derived
    PubMed: PMID 38819983 · NCT05024032 (SURMOUNT-CN) · Obesity
  3. Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
    Osumili B, Fan L, Paik JS, et al. · Diabetes Res Clin Pract · 2024 · Derived
    PubMed: PMID 38777128 · NCT03987919 (SURPASS-2) · Diabetes Mellitus, Type 2
  4. Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis.
    Onishi Y, Oura T, Takeuchi M, et al. · Diabetes Ther · 2024 · Derived
    PubMed: PMID 38310163 · NCT03861052 (SURPASS J-mono) · Diabetes Mellitus, Type 2
  5. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
    Malhotra A, Grunstein RR, Fietze I, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 38912654 · NCT05412004 (SURMOUNT-OSA) · Obesity
  6. Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial.
    Malhotra A, Bednarik J, Chakladar S, et al. · Contemp Clin Trials · 2024 · Derived
    PubMed: PMID 38547961 · NCT05412004 (SURMOUNT-OSA) · Obesity
  7. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
    Loomba R, Hartman ML, Lawitz EJ, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 38856224 · NCT04166773 (SYNERGY-NASH) · Non-alcoholic Fatty Liver Disease
  8. Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.
    Krumholz HM, de Lemos JA, Sattar N, et al. · Heart · 2024 · Derived
    PubMed: PMID 39084707 · NCT04184622 (SURMOUNT-1) · Obesity
  9. Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial.
    Ishii H, Oura T, Takeuchi M, et al. · Diabetes Ther · 2024 · Derived
    PubMed: PMID 37843771 · NCT03861052 (SURPASS J-mono) · Diabetes Mellitus, Type 2
  10. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups.
    Bi Y, Lu S, Tang J, et al. · Diabetes Ther · 2024 · Derived
    PubMed: PMID 38494574 · NCT04093752 · Diabetes Mellitus, Type 2
  11. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
    Aronne LJ, Sattar N, Horn DB, et al. · JAMA · 2024 · Derived
    PubMed: PMID 38078870 · NCT04660643 (SURMOUNT-4) · Obesity
  12. Liraglutide induced browning of visceral white adipose through regulation of miRNAs in high-fat-diet-induced obese mice.
    Zhao L, Li W, Zhang P, et al. · Endocrine · 2024 · Background
    PubMed: PMID 38378894 · NCT07309094 (ADIPO-CKD) · Obesity
  13. Approach to Obesity Treatment in Primary Care: A Review.
    Yanovski SZ, Yanovski JA · JAMA Intern Med · 2024 · Background
    PubMed: PMID 38466272 · NCT06935838 · Obesity
  14. Inflammation and resolution in obesity.
    Soták M, Clark M, Suur BE, et al. · Nat Rev Endocrinol · 2024 · Background
    PubMed: PMID 39448830 · NCT06935838 · Obesity
  15. Mild autonomous cortisol secretion: pathophysiology, comorbidities and management approaches.
    Prete A, Bancos I · Nat Rev Endocrinol · 2024 · Background
    PubMed: PMID 38649778 · NCT07573163
  16. Muscle matters: the effects of medically induced weight loss on skeletal muscle.
    Prado CM, Phillips SM, Gonzalez MC, et al. · Lancet Diabetes Endocrinol · 2024 · Background
    PubMed: PMID 39265590 · NCT06811324 · Obesity
  17. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
    Perkovic V, Tuttle KR, Rossing P, et al. · N Engl J Med · 2024 · Background
    PubMed: PMID 38785209 · NCT07309094 (ADIPO-CKD) · Obesity
  18. Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With HIV.
    Nguyen Q, Wooten D, Lee D, et al. · Clin Infect Dis · 2024 · Background
    PubMed: PMID 38501237 · NCT06935838 · Obesity
  19. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.
    Neeland IJ, Linge J, Birkenfeld AL, et al. · Diabetes Obes Metab · 2024 · Background
    PubMed: PMID 38937282 · NCT06811324 · Obesity
  20. Obesity drugs have another superpower: taming inflammation.
    Lenharo M · Nature · 2024 · Background
    PubMed: PMID 38278941 · NCT06935838 · Obesity
  21. Prevalence of Cardiometabolic Diseases Among Racial and Ethnic Subgroups in Adults - Behavioral Risk Factor Surveillance System, United States, 2013-2021.
    Koyama AK, McKeever Bullard K, Xu F, et al. · MMWR Morb Mortal Wkly Rep · 2024 · Background
    PubMed: PMID 38271277 · NCT06811324 · Obesity
  22. Changes in Basal and Bolus Insulin Requirements with Tirzepatide as an Adjunctive Therapy in Adults with Type 1 Diabetes Using Tandem Control-IQ.
    Karakus KE, Klein MP, Akturk HK, et al. · Diabetes Ther · 2024 · Background
    PubMed: PMID 38743306 · NCT07284511 (TZP) · Overweight
  23. Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review.
    Janež A, Guja C, Mitrakou A, et al. · Diabetes Ther · 2024 · Background
    PubMed: PMID 31902063 · NCT07284511 (TZP) · Overweight
  24. Comorbidities in Early Psoriatic Arthritis: Data From the Metabolic Disturbances in Psoriatic Arthritis Cohort Study.
    Ishchenko A, Pazmino S, Neerinckx B, et al. · Arthritis Care Res (Hoboken) · 2024 · Background
    PubMed: PMID 37667975 · NCT07443956 (COMBAT-PsA) · Obesity
  25. Challenges in Promoting Health Equity and Reducing Disparities in Access Across New and Established Technologies.
    Hoagland A, Kipping S · Can J Cardiol · 2024 · Background
    PubMed: PMID 38417572 · NCT06935838 · Obesity
  26. Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps.
    Dubin RL, Heymsfield SB, Ravussin E, et al. · Diabetes Obes Metab · 2024 · Background
    PubMed: PMID 39344838 · NCT07154719 (GRAMS) · Obesity
  27. Is Weight Loss-Induced Muscle Mass Loss Clinically Relevant?
    Conte C, Hall KD, Klein S, et al. · JAMA · 2024 · Background
    PubMed: PMID 38829659 · NCT06811324 · Obesity
  28. Methamphetamine Toxicities and Clinical Management.
    Coffin PO, Suen LW · NEJM Evid · 2024 · Background
    PubMed: PMID 38320504 · NCT06745128 · Obesity

2023 (21 papers)

  1. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
    Wadden TA, Chao AM, Machineni S, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 37840095 · NCT04657016 (SURMOUNT-3) · Obesity
  2. Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3.
    Viljoen A, Pantalone KM, Galindo RJ, et al. · Diabetes Ther · 2023 · Derived
    PubMed: PMID 37000390 · NCT03987919 (SURPASS-2) · Diabetes Mellitus, Type 2
  3. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
    Rosenstock J, Frías JP, Rodbard HW, et al. · JAMA · 2023 · Derived
    PubMed: PMID 37786396 · NCT04537923 (SURPASS-6) · Diabetes Mellitus, Type 2
  4. Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates.
    Reitzel SB, Bøgelund M, Basse A, et al. · Curr Med Res Opin · 2023 · Derived
    PubMed: PMID 37415503 · NCT03987919 (SURPASS-2) · Diabetes Mellitus, Type 2
  5. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.
    Heise T, DeVries JH, Urva S, et al. · Diabetes Care · 2023 · Derived
    PubMed: PMID 36857477 · NCT03951753 · Diabetes Mellitus, Type 2
  6. Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial.
    Hankosky ER, Wang H, Neff LM, et al. · Diabetes Obes Metab · 2023 · Derived
    PubMed: PMID 37700443 · NCT04184622 (SURMOUNT-1) · Obesity
  7. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Garvey WT, Frias JP, Jastreboff AM, et al. · Lancet · 2023 · Derived
    PubMed: PMID 37385275 · NCT04657003 (SURMOUNT-2) · Obesity
  8. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial.
    Gao L, Lee BW, Chawla M, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 37231074 · NCT04093752 · Diabetes Mellitus, Type 2
  9. A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes.
    Feng P, Sheng X, Ji Y, et al. · Adv Ther · 2023 · Derived
    PubMed: PMID 37285081 · NCT04235959 · Diabetes Mellitus, Type 2
  10. Adipocyte- and Monocyte-Mediated Vicious Circle of Inflammation and Obesity (Review of Cellular and Molecular Mechanisms).
    Todosenko N, Khaziakhmatova O, Malashchenko V, et al. · Int J Mol Sci · 2023 · Background
    PubMed: PMID 37569635 · NCT06935838 · Obesity
  11. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.
    Tan B, Pan XH, Chew HSJ, et al. · Int J Obes (Lond) · 2023 · Background
    PubMed: PMID 37253796 · NCT06745128 · Obesity
  12. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments.
    Ruze R, Liu T, Zou X, et al. · Front Endocrinol (Lausanne) · 2023 · Background
    PubMed: PMID 37152942 · NCT07099742 · Obesity
  13. Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis.
    Pelsma ICM, Fassnacht M, Tsagarakis S, et al. · Eur J Endocrinol · 2023 · Background
    PubMed: PMID 37801655 · NCT07573163
  14. A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems.
    Peacock S, Frizelle I, Hussain S, et al. · Diabetes Ther · 2023 · Background
    PubMed: PMID 37017916 · NCT07284511 (TZP) · Overweight
  15. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
    Nicholls SJ, Bhatt DL, Buse JB, et al. · Am Heart J · 2023 · Background
    PubMed: PMID 37758044 · NCT06779929 · Diabetes Mellitus, Type 2
  16. Discrepancy in Metabolic Syndrome between Psoriatic Arthritis and Rheumatoid Arthritis: a Direct Comparison of Two Cohorts in One Center.
    Li B, Huang H, Zhao J, et al. · Rheumatol Ther · 2023 · Background
    PubMed: PMID 36264448 · NCT07443956 (COMBAT-PsA) · Obesity
  17. Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials.
    Kanbay M, Copur S, Siriopol D, et al. · Diabetes Obes Metab · 2023 · Background
    PubMed: PMID 37700437 · NCT07573163
  18. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.
    Fassnacht M, Tsagarakis S, Terzolo M, et al. · Eur J Endocrinol · 2023 · Background
    PubMed: PMID 37318239 · NCT07573163
  19. The Growing Challenge of Chronic Kidney Disease: An Overview of Current Knowledge.
    Borg R, Carlson N, Søndergaard J, et al. · Int J Nephrol · 2023 · Background
    PubMed: PMID 36908289 · NCT07309094 (ADIPO-CKD) · Obesity
  20. Optical coherence tomography-derived lipid core burden index and clinical outcomes: results from the CLIMA registry.
    Biccirè FG, Budassi S, Ozaki Y, et al. · Eur Heart J Cardiovasc Imaging · 2023 · Background
    PubMed: PMID 35718858 · NCT06606821 (IDEAL-COR) · Obesity
  21. Epidemiology and Management of Hypertension and Diabetes Mellitus in Patients with Mild Autonomous Cortisol Secretion: A Review.
    Araujo-Castro M, Reincke M, Lamas C, et al. · Biomedicines · 2023 · Background
    PubMed: PMID 38137336 · NCT07573163

2022 (26 papers)

  1. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
    Urva S, Quinlan T, Landry J, et al. · Clin Pharmacokinet · 2022 · Derived
    PubMed: PMID 35674880 · NCT03940742 · Hepatic Insufficiency
  2. Bacillus Calmette-Guérin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial.
    Ten Doesschate T, van der Vaart TW, Debisarun PA, et al. · Clin Microbiol Infect · 2022 · Derived
    PubMed: PMID 35489606 · NCT03987919 (SURPASS-2) · Diabetes Mellitus, Type 2
  3. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.
    Sattar N, McGuire DK, Pavo I, et al. · Nat Med · 2022 · Derived
    PubMed: PMID 35210595 · NCT03131687 · Diabetes Mellitus, Type 2
  4. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.
    Pirro V, Roth KD, Lin Y, et al. · J Clin Endocrinol Metab · 2022 · Derived
    PubMed: PMID 34608929 · NCT03131687 · Diabetes Mellitus, Type 2
  5. Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.
    Kaneko S · touchREV Endocrinol · 2022 · Derived
    PubMed: PMID 35949358 · NCT04255433 (SURPASS-CVOT) · Diabetes Mellitus, Type 2
  6. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.
    Kadowaki T, Chin R, Ozeki A, et al. · Lancet Diabetes Endocrinol · 2022 · Derived
    PubMed: PMID 35914542 · NCT03861039 · Diabetes Mellitus, Type 2
  7. Tirzepatide Once Weekly for the Treatment of Obesity.
    Jastreboff AM, Aronne LJ, Ahmad NN, et al. · N Engl J Med · 2022 · Derived
    PubMed: PMID 35658024 · NCT04184622 (SURMOUNT-1) · Obesity
  8. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.
    Inagaki N, Takeuchi M, Oura T, et al. · Lancet Diabetes Endocrinol · 2022 · Derived
    PubMed: PMID 35914543 · NCT03861052 (SURPASS J-mono) · Diabetes Mellitus, Type 2
  9. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T, Mari A, DeVries JH, et al. · Lancet Diabetes Endocrinol · 2022 · Derived
    PubMed: PMID 35468322 · NCT03951753 · Diabetes Mellitus, Type 2
  10. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.
    Heerspink HJL, Sattar N, Pavo I, et al. · Lancet Diabetes Endocrinol · 2022 · Derived
    PubMed: PMID 36152639 · NCT03730662 (SURPASS-4) · Diabetes Mellitus, Type 2
  11. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Gastaldelli A, Cusi K, Fernández Landó L, et al. · Lancet Diabetes Endocrinol · 2022 · Derived
    PubMed: PMID 35468325 · NCT03882970 (SURPASS-3) · Diabetes Mellitus, Type 2
  12. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
    Del Prato S, Kahn SE, Pavo I, et al. · Lancet · 2022 · Derived
    PubMed: PMID 34672967 · NCT03730662 (SURPASS-4) · Diabetes Mellitus, Type 2
  13. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D, Onishi Y, Norwood P, et al. · JAMA · 2022 · Derived
    PubMed: PMID 35133415 · NCT04039503 (SURPASS-5) · Diabetes Mellitus, Type 2
  14. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Battelino T, Bergenstal RM, Rodríguez A, et al. · Lancet Diabetes Endocrinol · 2022 · Derived
    PubMed: PMID 35468321 · NCT03882970 (SURPASS-3) · Diabetes Mellitus, Type 2
  15. American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary.
    Yip L, Duh QY, Wachtel H, et al. · JAMA Surg · 2022 · Background
    PubMed: PMID 35976622 · NCT07573163
  16. The 1 mg overnight dexamethasone suppression test: a danger to the adrenal gland?
    Vanek C, Loriaux L · Curr Opin Endocrinol Diabetes Obes · 2022 · Background
    PubMed: PMID 35799460 · NCT07573163
  17. Closed-Loop Insulin Delivery Systems: Past, Present, and Future Directions.
    Templer S · Front Endocrinol (Lausanne) · 2022 · Background
    PubMed: PMID 35733769 · NCT07284511 (TZP) · Overweight
  18. Using Participatory Methods to Assess PrEP Interest and Uptake Among Young People Living in the Southeastern US: A Mixed Methods Assessment.
    Stoner MCD, Bhushan NL, Maragh-Bass AC, et al. · AIDS Behav · 2022 · Background
    PubMed: PMID 34724592 · NCT06606821 (IDEAL-COR) · Obesity
  19. Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors : A Cross-Sectional Multicenter Study.
    Prete A, Subramanian A, Bancos I, et al. · Ann Intern Med · 2022 · Background
    PubMed: PMID 34978855 · NCT07573163
  20. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.
    Marx N, Husain M, Lehrke M, et al. · Circulation · 2022 · Background
    PubMed: PMID 36508493 · NCT06811324 · Obesity
  21. HIV-Related Immune Activation and Inflammation: Current Understanding and Strategies.
    Lv T, Cao W, Li T, et al. · J Immunol Res · 2022 · Background
    PubMed: PMID 34631899 · NCT06935838 · Obesity
  22. Systematic review and meta-analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis.
    Loganathan A, Kamalaraj N, El-Haddad C, et al. · Int J Rheum Dis · 2022 · Background
    PubMed: PMID 34076348 · NCT07443956 (COMBAT-PsA) · Obesity
  23. Impact of obesity on quality of life, psychological status, and disease activity in psoriatic arthritis: a multi‑center study.
    Gok K, Nas K, Tekeoglu I, et al. · Rheumatol Int · 2022 · Background
    PubMed: PMID 34453579 · NCT07443956 (COMBAT-PsA) · Obesity
  24. Tirzepatide: A Systematic Update.
    Forzano I, Varzideh F, Avvisato R, et al. · Int J Mol Sci · 2022 · Background
    PubMed: PMID 36498958 · NCT07099742 · Obesity
  25. 6. Glycemic Targets: Standards of Care in Diabetes-2023.
    ElSayed NA, Aleppo G, Aroda VR, et al. · Diabetes Care · 2022 · Background
    PubMed: PMID 36507646 · NCT06606821 (IDEAL-COR) · Obesity
  26. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US.
    Eberly LA, Yang L, Essien UR, et al. · JAMA Health Forum · 2022 · Background
    PubMed: PMID 35977298 · NCT06811324 · Obesity

2021 (28 papers)

  1. Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
    Urva S, Quinlan T, Landry J, et al. · Clin Pharmacokinet · 2021 · Derived
    PubMed: PMID 33778934 · NCT03482024 · Kidney Failure, Chronic
  2. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Rosenstock J, Wysham C, Frías JP, et al. · Lancet · 2021 · Derived
    PubMed: PMID 34186022 · NCT03954834 (SURPASS-1) · Diabetes Mellitus, Type 2
  3. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B, Giorgino F, Jódar E, et al. · Lancet · 2021 · Derived
    PubMed: PMID 34370970 · NCT03882970 (SURPASS-3) · Diabetes Mellitus, Type 2
  4. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
    Hartman ML, Sanyal AJ, Loomba R, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 32291277 · NCT03131687 · Diabetes Mellitus, Type 2
  5. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP, Davies MJ, Rosenstock J, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 34170647 · NCT03987919 (SURPASS-2) · Diabetes Mellitus, Type 2
  6. Obesity in adults: a clinical practice guideline.
    Wharton S, Lau DCW, Vallis M, et al. · CMAJ · 2021 · Background
    PubMed: PMID 32753461 · NCT06935838 · Obesity
  7. Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland.
    Vallejo-Yagüe E, Burkard T, Möller B, et al. · J Clin Med · 2021 · Background
    PubMed: PMID 34300360 · NCT07443956 (COMBAT-PsA) · Obesity
  8. Alleviating carbohydrate counting with a FiASP-plus-pramlintide closed-loop delivery system (artificial pancreas): Feasibility and pilot studies.
    Tsoukas MA, Cohen E, Legault L, et al. · Diabetes Obes Metab · 2021 · Background
    PubMed: PMID 34047449 · NCT07284511 (TZP) · Overweight
  9. Depression: another cortisol-related comorbidity in patients with adrenal incidentalomas and (possible) autonomous cortisol secretion.
    Šojat AS, Dunjić-Kostić B, Marina LV, et al. · J Endocrinol Invest · 2021 · Background
    PubMed: PMID 33528757 · NCT07573163
  10. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study.
    Roth GA, Mensah GA, Johnson CO, et al. · J Am Coll Cardiol · 2021 · Background
    PubMed: PMID 33309175 · NCT06606821 (IDEAL-COR) · Obesity
  11. Adrenal Incidentalomas are Tied to Increased Risk of Diabetes: Findings from a Prospective Study.
    Reimondo G, Castellano E, Grosso M, et al. · J Clin Endocrinol Metab · 2021 · Background
    PubMed: PMID 31900474 · NCT07573163
  12. Obesity Phenotypes, Diabetes, and Cardiovascular Diseases.
    Piché ME, Tchernof A, Després JP, et al. · Circ Res · 2021 · Background
    PubMed: PMID 32437302 · NCT06606821 (IDEAL-COR) · Obesity
  13. Effect of Alirocumab and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaque in Coronary Artery Disease Seen on Near-Infrared Spectroscopy Intravascular Ultrasound (ANTARES).
    Otake H, Tanimura K, Sugizaki Y, et al. · Circ Rep · 2021 · Background
    PubMed: PMID 33693121 · NCT06606821 (IDEAL-COR) · Obesity
  14. Mental Health in Patients With Adrenal Incidentalomas: Is There a Relation With Different Degrees of Cortisol Secretion?
    Morelli V, Ghielmetti A, Caldiroli A, et al. · J Clin Endocrinol Metab · 2021 · Background
    PubMed: PMID 33017843 · NCT07573163
  15. Framing Cause-Effect Relationship of Acute Coronary Syndrome in Patients with Chronic Kidney Disease.
    Moisi MI, Bungau SG, Vesa CM, et al. · Diagnostics (Basel) · 2021 · Background
    PubMed: PMID 34441451 · NCT07309094 (ADIPO-CKD) · Obesity
  16. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
    Lundgren JR, Janus C, Jensen SBK, et al. · N Engl J Med · 2021 · Background
    PubMed: PMID 33951361 · NCT07154719 (GRAMS) · Obesity
  17. Contemporary Trends and Outcomes in Patients With ST-Segment Elevation Myocardial Infarction and End-Stage Renal Disease on Dialysis: Insight from the National Inpatient Sample.
    Khan MZ, Syed M, Osman M, et al. · Cardiovasc Revasc Med · 2021 · Background
    PubMed: PMID 32444271 · NCT07309094 (ADIPO-CKD) · Obesity
  18. Comorbidities in psoriatic arthritis: a systematic review and meta-analysis.
    Gupta S, Syrimi Z, Hughes DM, et al. · Rheumatol Int · 2021 · Background
    PubMed: PMID 33423070 · NCT07443956 (COMBAT-PsA) · Obesity
  19. Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis.
    Green A, Shaddick G, Charlton R, et al. · Br J Dermatol · 2021 · Background
    PubMed: PMID 31209855 · NCT07443956 (COMBAT-PsA) · Obesity
  20. Psoriatic arthritis is associated with adverse body composition predictive of greater coronary heart disease and type 2 diabetes propensity - a cross-sectional study.
    Ferguson LD, Linge J, Dahlqvist Leinhard O, et al. · Rheumatology (Oxford) · 2021 · Background
    PubMed: PMID 33147607 · NCT07443956 (COMBAT-PsA) · Obesity
  21. Cardiorenal Fat: A Cardiovascular Risk Factor With Implications in Chronic Kidney Disease.
    D'Marco L, Puchades MJ, Panizo N, et al. · Front Med (Lausanne) · 2021 · Background
    PubMed: PMID 34113631 · NCT07309094 (ADIPO-CKD) · Obesity
  22. Aging, obesity, sarcopenia and the effect of diet and exercise intervention.
    Colleluori G, Villareal DT · Exp Gerontol · 2021 · Background
    PubMed: PMID 34562568 · NCT06811324 · Obesity
  23. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
    Capehorn MS, Catarig AM, Furberg JK, et al. · Diabetes Metab · 2021 · Background
    PubMed: PMID 31539622 · NCT07284511 (TZP) · Overweight
  24. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.
    Borén J, Chapman MJ, Krauss RM, et al. · Eur Heart J · 2021 · Background
    PubMed: PMID 32052833 · NCT06606821 (IDEAL-COR) · Obesity
  25. Approach to the Patient With Adrenal Incidentaloma.
    Bancos I, Prete A · J Clin Endocrinol Metab · 2021 · Background
    PubMed: PMID 34260734 · NCT07573163
  26. CAV1-CAVIN1-LC3B-mediated autophagy regulates high glucose-stimulated LDL transcytosis.
    Bai X, Yang X, Jia X, et al. · Autophagy · 2021 · Background
    PubMed: PMID 31448673 · NCT06606821 (IDEAL-COR) · Obesity
  27. Impaired kidney function is associated with lower quality of life among community-dwelling older adults : The screening for CKD among older people across Europe (SCOPE) study.
    Artzi-Medvedik R, Kob R, Fabbietti P, et al. · BMC Geriatr · 2021 · Background
    PubMed: PMID 33008306 · NCT07309094 (ADIPO-CKD) · Obesity
  28. The role of overweight and obesity in adverse cardiovascular disease mortality trends: an analysis of multiple cause of death data from Australia and the USA.
    Adair T, Lopez AD · BMC Med · 2021 · Background
    PubMed: PMID 32746822 · NCT06606821 (IDEAL-COR) · Obesity

2020 (10 papers)

  1. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping.
    Zwanenburg A, Vallières M, Abdalah MA, et al. · Radiology · 2020 · Trial result
    PubMed: PMID 32154773 · NCT07567378 (CARTIZ) · Obesity
  2. Is the long-term decline in cardiovascular-disease mortality in high-income countries over? Evidence from national vital statistics.
    Lopez AD, Adair T · Int J Epidemiol · 2020 · Background
    PubMed: PMID 31378814 · NCT06606821 (IDEAL-COR) · Obesity
  3. Hypertension in CKD: Core Curriculum 2019.
    Ku E, Lee BJ, Wei J, et al. · Am J Kidney Dis · 2020 · Background
    PubMed: PMID 30898362 · NCT07309094 (ADIPO-CKD) · Obesity
  4. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Kristensen SL, Rørth R, Jhund PS, et al. · Lancet Diabetes Endocrinol · 2020 · Background
    PubMed: PMID 31422062 · NCT06606821 (IDEAL-COR) · Obesity
  5. Adrenal incidentaloma: cardiovascular and metabolic effects of mild cortisol excess.
    Kelsall A, Iqbal A, Newell-Price J, et al. · Gland Surg · 2020 · Background
    PubMed: PMID 32206602 · NCT07573163
  6. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials.
    Giugliano D, Maiorino MI, Bellastella G, et al. · Diabetes Obes Metab · 2020 · Background
    PubMed: PMID 31373167 · NCT07309094 (ADIPO-CKD) · Obesity
  7. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    GBD Chronic Kidney Disease Collaboration · Lancet · 2020 · Background
    PubMed: PMID 32061315 · NCT07309094 (ADIPO-CKD) · Obesity
  8. Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions.
    Ferguson LD, Siebert S, McInnes IB, et al. · Nat Rev Rheumatol · 2020 · Background
    PubMed: PMID 31292564 · NCT07443956 (COMBAT-PsA) · Obesity
  9. Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study.
    Ebbehoj A, Li D, Kaur RJ, et al. · Lancet Diabetes Endocrinol · 2020 · Background
    PubMed: PMID 33065059 · NCT07573163
  10. Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials.
    Caruso I, Cignarelli A, Giorgino F, et al. · Trends Endocrinol Metab · 2020 · Background
    PubMed: PMID 31401015 · NCT06606821 (IDEAL-COR) · Obesity

2019 (11 papers)

  1. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP, Nauck MA, Van J, et al. · Lancet · 2019 · Derived
    PubMed: PMID 30293770 · NCT03131687 · Diabetes Mellitus, Type 2
  2. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T, Sloop KW, Loghin C, et al. · Mol Metab · 2019 · Derived
    PubMed: PMID 30473097 · NCT02759107 · Diabetes Mellitus, Type 2
  3. The age-related loss of skeletal muscle mass and function: Measurement and physiology of muscle fibre atrophy and muscle fibre loss in humans.
    Wilkinson DJ, Piasecki M, Atherton PJ, et al. · Ageing Res Rev · 2019 · Background
    PubMed: PMID 30048806 · NCT06811324 · Obesity
  4. Autonomous hypercortisolism: definition and clinical implications.
    Reimondo G, Puglisi S, Pia A, et al. · Minerva Endocrinol · 2019 · Background
    PubMed: PMID 29963828 · NCT07573163
  5. Endothelial permeability, LDL deposition, and cardiovascular risk factors-a review.
    Mundi S, Massaro M, Scoditti E, et al. · Cardiovasc Res · 2019 · Background
    PubMed: PMID 29228169 · NCT06606821 (IDEAL-COR) · Obesity
  6. The expanding burden of idiopathic intracranial hypertension.
    Mollan SP, Aguiar M, Evison F, et al. · Eye (Lond) · 2019 · Background
    PubMed: PMID 30356129 · NCT07191873 (TIIHT) · Headache
  7. Monocyte activation and cardiovascular disease in HIV infection.
    Liang H, Xie Z, Shen T, et al. · Cell Mol Immunol · 2019 · Background
    PubMed: PMID 29082920 · NCT06935838 · Obesity
  8. Sarcopenia: Aging-Related Loss of Muscle Mass and Function.
    Larsson L, Degens H, Li M, et al. · Physiol Rev · 2019 · Background
    PubMed: PMID 30427277 · NCT06811324 · Obesity
  9. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
    Hernandez AF, Green JB, Janmohamed S, et al. · Lancet · 2019 · Background
    PubMed: PMID 30291013 · NCT06606821 (IDEAL-COR) · Obesity
  10. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Gerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet · 2019 · Background
    PubMed: PMID 31189511 · NCT06606821 (IDEAL-COR) · Obesity
  11. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018.
    Foster NC, Beck RW, Miller KM, et al. · Diabetes Technol Ther · 2019 · Background
    PubMed: PMID 30657336 · NCT07284511 (TZP) · Overweight

2018 (8 papers)

  1. Detecting human coronary inflammation by imaging perivascular fat.
    Antonopoulos AS, Sanna F, Sabharwal N, et al. · Sci Transl Med · 2018 · Trial result
    PubMed: PMID 28701474 · NCT07567378 (CARTIZ) · Obesity
  2. Use of Diabetes Treatment Satisfaction Questionnaire in Diabetes Care: Importance of Patient-Reported Outcomes.
    Saisho Y · Int J Environ Res Public Health · 2018 · Background
    PubMed: PMID 29747423 · NCT07284511 (TZP) · Overweight
  3. Beyond the Ability to Pay: The Health Status of Native Hawaiians and Other Pacific Islanders in Relationship to Health Insurance.
    Morisako AK, Tauali'i M, Ambrose AJH, et al. · Hawaii J Med Public Health · 2018 · Background
    PubMed: PMID 28435757 · NCT06935838 · Obesity
  4. Obesity and cardiovascular disease: friend or foe?
    Kim SH, Després JP, Koh KK, et al. · Eur Heart J · 2018 · Background
    PubMed: PMID 26685971 · NCT06606821 (IDEAL-COR) · Obesity
  5. High-density lipoprotein cholesterol associated with change in coronary plaque lipid burden assessed by near infrared spectroscopy.
    Honda S, Sidharta SL, Shishikura D, et al. · Atherosclerosis · 2018 · Background
    PubMed: PMID 28881268 · NCT06606821 (IDEAL-COR) · Obesity
  6. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories.
    Foreman KJ, Marquez N, Dolgert A, et al. · Lancet · 2018 · Background
    PubMed: PMID 30340847 · NCT07309094 (ADIPO-CKD) · Obesity
  7. Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and change over time.
    Fisher L, Hessler D, Polonsky W, et al. · J Diabetes Complications · 2018 · Background
    PubMed: PMID 27118163 · NCT07284511 (TZP) · Overweight
  8. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
    Ahmann AJ, Capehorn M, Charpentier G, et al. · Diabetes Care · 2018 · Background
    PubMed: PMID 29246950 · NCT07284511 (TZP) · Overweight

2017 (3 papers)

  1. Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management.
    Mollan SP, Ali F, Hassan-Smith G, et al. · J Neurol Neurosurg Psychiatry · 2017 · Background
    PubMed: PMID 26888960 · NCT07191873 (TIIHT) · Headache
  2. Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes After Intensive Statin Treatment: The YELLOW II Study.
    Kini AS, Vengrenyuk Y, Shameer K, et al. · J Am Coll Cardiol · 2017 · Background
    PubMed: PMID 27989886 · NCT06606821 (IDEAL-COR) · Obesity
  3. Heart Failure Increases the Risk of Adverse Renal Outcomes in Patients With Normal Kidney Function.
    George LK, Koshy SKG, Molnar MZ, et al. · Circ Heart Fail · 2017 · Background
    PubMed: PMID 28765150 · NCT07309094 (ADIPO-CKD) · Obesity

2016 (7 papers)

  1. GLP1 protects cardiomyocytes from palmitate-induced apoptosis via Akt/GSK3b/b-catenin pathway.
    Ying Y, Zhu H, Liang Z, et al. · J Mol Endocrinol · 2016 · Background
    PubMed: PMID 26386043 · NCT07309094 (ADIPO-CKD) · Obesity
  2. Controversies: Optic nerve sheath fenestration versus shunt placement for the treatment of idiopathic intracranial hypertension.
    Spitze A, Lam P, Al-Zubidi N, et al. · Indian J Ophthalmol · 2016 · Background
    PubMed: PMID 25449938 · NCT07191873 (TIIHT) · Headache
  3. Role of near-infrared spectroscopy in intravascular coronary imaging.
    Negi SI, Didier R, Ota H, et al. · Cardiovasc Revasc Med · 2016 · Background
    PubMed: PMID 26242984 · NCT06606821 (IDEAL-COR) · Obesity
  4. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants.
    NCD Risk Factor Collaboration (NCD-RisC) · Lancet · 2016 · Background
    PubMed: PMID 27115820 · NCT06606821 (IDEAL-COR) · Obesity
  5. Accuracy of Carbohydrate Counting in Adults.
    Meade LT, Rushton WE · Clin Diabetes · 2016 · Background
    PubMed: PMID 27621531 · NCT07284511 (TZP) · Overweight
  6. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    Marso SP, Daniels GH, Brown-Frandsen K, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27295427 · NCT07284511 (TZP) · Overweight
  7. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    Marso SP, Bain SC, Consoli A, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27633186 · NCT07284511 (TZP) · Overweight

2015 (5 papers)

  1. Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study.
    Räber L, Taniwaki M, Zaugg S, et al. · Eur Heart J · 2015 · Background
    PubMed: PMID 25182248 · NCT06606821 (IDEAL-COR) · Obesity
  2. Combined IVUS and NIRS detection of fibroatheromas: histopathological validation in human coronary arteries.
    Kang SJ, Mintz GS, Pu J, et al. · JACC Cardiovasc Imaging · 2015 · Background
    PubMed: PMID 25577445 · NCT06606821 (IDEAL-COR) · Obesity
  3. Total body skeletal muscle mass: estimation by creatine (methyl-d3) dilution in humans.
    Clark RV, Walker AC, O'Connor-Semmes RL, et al. · J Appl Physiol (1985) · 2015 · Background
    PubMed: PMID 24764133 · NCT06811324 · Obesity
  4. Increased GIP signaling induces adipose inflammation via a HIF-1α-dependent pathway and impairs insulin sensitivity in mice.
    Chen S, Okahara F, Osaki N, et al. · Am J Physiol Endocrinol Metab · 2015 · Background
    PubMed: PMID 25537494 · NCT06606821 (IDEAL-COR) · Obesity
  5. Pharmacological management of obesity: an endocrine Society clinical practice guideline.
    Apovian CM, Aronne LJ, Bessesen DH, et al. · J Clin Endocrinol Metab · 2015 · Background
    PubMed: PMID 25590212 · NCT06935838 · Obesity

2014 (2 papers)

  1. Adipokines: a link between obesity and cardiovascular disease.
    Nakamura K, Fuster JJ, Walsh K, et al. · J Cardiol · 2014 · Background
    PubMed: PMID 24355497 · NCT06606821 (IDEAL-COR) · Obesity
  2. Epidemiology and risk factors for idiopathic intracranial hypertension.
    Chen J, Wall M · Int Ophthalmol Clin · 2014 · Background
    PubMed: PMID 24296367 · NCT07191873 (TIIHT) · Headache

2013 (3 papers)

  1. Arterial stiffening precedes systolic hypertension in diet-induced obesity.
    Weisbrod RM, Shiang T, Al Sayah L, et al. · Hypertension · 2013 · Background
    PubMed: PMID 24060894 · NCT06606821 (IDEAL-COR) · Obesity
  2. Subsequent development of fibroatheromas with inflamed fibrous caps can be predicted by intracoronary near infrared spectroscopy.
    Patel D, Hamamdzic D, Llano R, et al. · Arterioscler Thromb Vasc Biol · 2013 · Background
    PubMed: PMID 23288155 · NCT06606821 (IDEAL-COR) · Obesity
  3. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy).
    Kini AS, Baber U, Kovacic JC, et al. · J Am Coll Cardiol · 2013 · Background
    PubMed: PMID 23644090 · NCT06606821 (IDEAL-COR) · Obesity

2012 (2 papers)

  1. Obesity and the risk of psoriatic arthritis: a population-based study.
    Love TJ, Zhu Y, Zhang Y, et al. · Ann Rheum Dis · 2012 · Background
    PubMed: PMID 22586165 · NCT07443956 (COMBAT-PsA) · Obesity
  2. Obesity and risk of incident psoriatic arthritis in US women.
    Li W, Han J, Qureshi AA, et al. · Ann Rheum Dis · 2012 · Background
    PubMed: PMID 22562978 · NCT07443956 (COMBAT-PsA) · Obesity

2011 (2 papers)

  1. Should C-reactive protein be a target of therapy?
    Oh J, Teoh H, Leiter LA, et al. · Diabetes Care · 2011 · Background
    PubMed: PMID 21525448 · NCT06606821 (IDEAL-COR) · Obesity
  2. Psychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes.
    Gonder-Frederick LA, Schmidt KM, Vajda KA, et al. · Diabetes Care · 2011 · Background
    PubMed: PMID 21346182 · NCT07284511 (TZP) · Overweight

2010 (3 papers)

  1. Global estimates of the prevalence of diabetes for 2010 and 2030.
    Shaw JE, Sicree RA, Zimmet PZ, et al. · Diabetes Res Clin Pract · 2010 · Background
    PubMed: PMID 19896746 · NCT07309094 (ADIPO-CKD) · Obesity
  2. Increased expression and secretion of resistin in epicardial adipose tissue of patients with acute coronary syndrome.
    Langheim S, Dreas L, Veschini L, et al. · Am J Physiol Heart Circ Physiol · 2010 · Background
    PubMed: PMID 20061546 · NCT06606821 (IDEAL-COR) · Obesity
  3. Obesity and its relationship to addictions: is overeating a form of addictive behavior?
    Barry D, Clarke M, Petry NM, et al. · Am J Addict · 2010 · Background
    PubMed: PMID 19874165 · NCT06745128 · Obesity

2009 (3 papers)

  1. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas.
    Zeiger MA, Thompson GB, Duh QY, et al. · Endocr Pract · 2009 · Background
    PubMed: PMID 19632967 · NCT07573163
  2. Obesity among patients with HIV: the latest epidemic.
    Crum-Cianflone N, Tejidor R, Medina S, et al. · AIDS Patient Care STDS · 2009 · Background
    PubMed: PMID 19072098 · NCT06935838 · Obesity
  3. Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells.
    Carraro-Lacroix LR, Malnic G, Girardi AC, et al. · Am J Physiol Renal Physiol · 2009 · Background
    PubMed: PMID 19776173 · NCT07309094 (ADIPO-CKD) · Obesity

2008 (3 papers)

  1. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas.
    Weinzimer SA, Steil GM, Swan KL, et al. · Diabetes Care · 2008 · Background
    PubMed: PMID 18252903 · NCT07284511 (TZP) · Overweight
  2. Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study.
    Kulich KR, Madisch A, Pacini F, et al. · Health Qual Life Outcomes · 2008 · Background
    PubMed: PMID 18237386 · NCT06745128 · Obesity
  3. Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex.
    Hou J, Renigunta A, Konrad M, et al. · J Clin Invest · 2008 · Background
    PubMed: PMID 18188451 · NCT06606821 (IDEAL-COR) · Obesity

2007 (2 papers)

  1. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II.
    Setty AR, Curhan G, Choi HK, et al. · Arch Intern Med · 2007 · Background
    PubMed: PMID 17698691 · NCT07443956 (COMBAT-PsA) · Obesity
  2. The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton Pleasure Scale (SHAPS).
    Franken IH, Rassin E, Muris P, et al. · J Affect Disord · 2007 · Background
    PubMed: PMID 16996138 · NCT06745128 · Obesity

2005 (1 paper)

  1. Psoriatic arthritis: epidemiology, clinical features, course, and outcome.
    Gladman DD, Antoni C, Mease P, et al. · Ann Rheum Dis · 2005 · Background
    PubMed: PMID 15708927 · NCT07443956 (COMBAT-PsA) · Obesity

2004 (1 paper)

  1. Obesity is associated with macrophage accumulation in adipose tissue.
    Weisberg SP, McCann D, Desai M, et al. · J Clin Invest · 2004 · Background
    PubMed: PMID 14679176 · NCT06606821 (IDEAL-COR) · Obesity

2001 (1 paper)

  1. Psychometric properties and factor structure of the Three-Factor Eating Questionnaire (TFEQ) in obese men and women. Results from the Swedish Obese Subjects (SOS) study.
    Karlsson J, Persson LO, Sjöström L, et al. · Int J Obes Relat Metab Disord · 2001 · Background
    PubMed: PMID 11126230 · NCT07284511 (TZP) · Overweight

2000 (2 papers)

  1. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions.
    Virmani R, Kolodgie FD, Burke AP, et al. · Arterioscler Thromb Vasc Biol · 2000 · Background
    PubMed: PMID 10807742 · NCT06606821 (IDEAL-COR) · Obesity
  2. Intramuscular lipid content is increased in obesity and decreased by weight loss.
    Goodpaster BH, Theriault R, Watkins SC, et al. · Metabolism · 2000 · Background
    PubMed: PMID 10778870 · NCT07154719 (GRAMS) · Obesity

1998 (1 paper)

  1. Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study.
    Howard G, Wagenknecht LE, Burke GL, et al. · JAMA · 1998 · Background
    PubMed: PMID 9440661 · NCT06606821 (IDEAL-COR) · Obesity

1988 (1 paper)

  1. Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations.
    Sobell LC, Sobell MB, Leo GI, et al. · Br J Addict · 1988 · Background
    PubMed: PMID 3395719 · NCT06745128 · Obesity

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).